Laboratorio Reig Jofre, S.A. (RJF.MC)
EUR 2.97
(2.06%)
EUR 2.97
(2.06%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 19.83 Million EUR | -22.02% |
| 2022 | 25.43 Million EUR | -48.14% |
| 2021 | 49.05 Million EUR | 14.63% |
| 2020 | 42.79 Million EUR | 0.7% |
| 2019 | 42.49 Million EUR | 101.83% |
| 2018 | 21.05 Million EUR | 23.19% |
| 2017 | 17.09 Million EUR | -0.83% |
| 2016 | 17.23 Million EUR | 66.52% |
| 2015 | 10.34 Million EUR | -15.26% |
| 2014 | 12.21 Million EUR | 0.0% |
| 2013 | - EUR | -100.0% |
| 2012 | 257 Thousand EUR | -98.54% |
| 2011 | 17.65 Million EUR | 8512.68% |
| 2010 | 205 Thousand EUR | -96.94% |
| 2009 | 6.7 Million EUR | -89.2% |
| 2008 | 62.12 Million EUR | -16.67% |
| 2007 | 74.55 Million EUR | 6.33% |
| 2006 | 70.11 Million EUR | 73.44% |
| 2005 | 40.42 Million EUR | 3359.99% |
| 2004 | 1.16 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 22.58 Million EUR | 13.86% |
| 2024 Q3 | 33.36 Million EUR | 65.02% |
| 2024 Q2 | 20.21 Million EUR | -10.49% |
| 2023 Q3 | 26.43 Million EUR | -13.73% |
| 2023 Q4 | 19.83 Million EUR | -24.96% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 FY | 19.83 Million EUR | -22.02% |
| 2023 Q2 | 30.64 Million EUR | 0.0% |
| 2022 Q4 | 25.43 Million EUR | -39.06% |
| 2022 FY | 25.43 Million EUR | -48.14% |
| 2022 Q3 | 41.74 Million EUR | -7.53% |
| 2022 Q2 | 45.13 Million EUR | 0.0% |
| 2021 Q2 | 43.91 Million EUR | 11.71% |
| 2021 Q1 | 39.31 Million EUR | -8.13% |
| 2021 FY | 49.05 Million EUR | 14.63% |
| 2021 Q4 | 49.05 Million EUR | 1.16% |
| 2021 Q3 | 48.49 Million EUR | 10.42% |
| 2020 Q2 | 48 Million EUR | 27.96% |
| 2020 Q4 | 42.79 Million EUR | -4.14% |
| 2020 Q3 | 44.64 Million EUR | -7.01% |
| 2020 FY | 42.79 Million EUR | 0.7% |
| 2020 Q1 | 37.51 Million EUR | -11.71% |
| 2019 Q2 | 30.64 Million EUR | 40.54% |
| 2019 Q4 | 42.49 Million EUR | 34.92% |
| 2019 FY | 42.49 Million EUR | 101.83% |
| 2019 Q1 | 21.8 Million EUR | 3.55% |
| 2019 Q3 | 31.49 Million EUR | 2.79% |
| 2018 Q3 | 20.54 Million EUR | 15.31% |
| 2018 Q1 | 16.72 Million EUR | -2.14% |
| 2018 FY | 21.05 Million EUR | 23.19% |
| 2018 Q4 | 21.05 Million EUR | 2.47% |
| 2018 Q2 | 17.82 Million EUR | 6.55% |
| 2017 Q1 | 16.46 Million EUR | -4.47% |
| 2017 FY | 17.09 Million EUR | -0.83% |
| 2017 Q2 | 15.67 Million EUR | -4.77% |
| 2017 Q4 | 17.09 Million EUR | 6.18% |
| 2017 Q3 | 16.09 Million EUR | 2.66% |
| 2016 Q4 | 17.23 Million EUR | 90.63% |
| 2016 FY | 17.23 Million EUR | 66.52% |
| 2016 Q1 | 9.92 Million EUR | -4.15% |
| 2016 Q2 | 9.49 Million EUR | -4.33% |
| 2016 Q3 | 9.04 Million EUR | -4.75% |
| 2015 Q4 | 10.34 Million EUR | -5.13% |
| 2015 Q3 | 10.9 Million EUR | -3.38% |
| 2015 FY | 10.34 Million EUR | -15.26% |
| 2015 Q2 | 11.29 Million EUR | -3.91% |
| 2015 Q1 | 11.75 Million EUR | -3.79% |
| 2014 Q2 | - EUR | 0.0% |
| 2014 Q3 | - EUR | 0.0% |
| 2014 FY | 12.21 Million EUR | 0.0% |
| 2014 Q4 | 12.21 Million EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 Q2 | - EUR | 0.0% |
| 2013 FY | - EUR | -100.0% |
| 2013 Q4 | - EUR | 0.0% |
| 2013 Q3 | - EUR | 0.0% |
| 2013 Q1 | - EUR | -100.0% |
| 2012 FY | 257 Thousand EUR | -98.54% |
| 2012 Q2 | 8.05 Million EUR | -20.89% |
| 2012 Q3 | - EUR | -100.0% |
| 2012 Q4 | 257 Thousand EUR | 0.0% |
| 2012 Q1 | 10.18 Million EUR | -42.31% |
| 2011 FY | 17.65 Million EUR | 8512.68% |
| 2011 Q4 | 17.65 Million EUR | 0.0% |
| 2011 Q2 | 75.12 Million EUR | 0.0% |
| 2010 Q1 | - EUR | 0.0% |
| 2010 FY | 205 Thousand EUR | -96.94% |
| 2010 Q2 | 77.61 Million EUR | 0.0% |
| 2009 FY | 6.7 Million EUR | -89.2% |
| 2008 FY | 62.12 Million EUR | -16.67% |
| 2007 FY | 74.55 Million EUR | 6.33% |
| 2006 FY | 70.11 Million EUR | 73.44% |
| 2005 FY | 40.42 Million EUR | 3359.99% |
| 2004 FY | 1.16 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Almirall, S.A. | 386.03 Million EUR | 94.861% |
| Faes Farma, S.A. | 4.37 Million EUR | -353.625% |